Histone Deacetylase Inhibitors As Venetoclax-Sensitising Partners in Acute Myeloid Leukaemia: Mechanisms, Pharmacology, and Translational Perspectives

The authors discuss the rationale and evidence for combining histone deacetylase inhibitors with venetoclax in AML, including mechanisms of action, resistance pathways, and preclinical and clinical data